
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is well-positioned in the market with its innovative discovery platform and multiple promising drug candidates, making it a strong investment for those with a long-term outlook. The company's expected sales targets and positive financial outlook add to its appeal, despite potential competition in the market. With the demand for effective and convenient treatments for central nervous system disorders on the rise, MapLight Therapeutics has the potential for significant growth and success in the future.
Bears say
MapLight Therapeutics is a clinical-stage biopharmaceutical company with a unique approach to targeting central nervous system disorders. While the potential of ML-007C-MA is promising, success is far from guaranteed and the company faces stiff competition in the market. Furthermore, the potential for ML-004 to treat ASD, while intriguing, is still in early stages and has no guarantee of success, making it a risky investment.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares